Revelation Biosciences, Inc.
REVB · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $3,756 | $1,806 | $7,664 | $7,668 |
| - Cash | $12,708 | $5,174 | $3,705 | $6,499 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | -$8,953 | -$3,368 | $3,959 | $1,169 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$1,900 | -$2,454 | -$2,088 | -$1,747 |
| % Margin | – | – | – | – |
| Net Income | -$1,907 | -$2,444 | -$2,051 | -$1,726 |
| % Margin | – | – | – | – |
| EPS Diluted | -1.77 | -7.01 | -2.11 | -4.98 |
| % Growth | 74.8% | -232.2% | 57.6% | – |
| Operating Cash Flow | -$1,589 | -$1,919 | -$2,794 | -$3,748 |
| Capital Expenditures | $0 | $0 | $0 | $18 |
| Free Cash Flow | -$1,589 | -$1,919 | -$2,794 | -$3,730 |